According to a person familiar with the matter, the Trump administration's revived rule to end rebates that drugmakers give to middlemen in Medicare is awaiting approval from the Office of Management and Budget (OMB) and a final rule could be imminent, reported The Wall Street Journal.
The administration has argued that the rule would drive down the prices consumers pay for prescription drugs.
An earlier version of the rule, a signature part of President Trump's plan to lower drug prices, was pulled last year because some White House advisers raised concerns that it could boost Medicare premiums.
The Department of Health and Human Services' decision to submit the rule to the OMB shows the administration plans to continue making health-related rules and regulations before January 20, when President-elect Joe Biden is scheduled to be inaugurated, according to the news source.
To read more NewsPoints articles, click here.